<DOC>
	<DOCNO>NCT02285088</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetic , pharmacodynamic effect GBT440 compare placebo healthy subject subject sickle cell disease ( SCD ) .</brief_summary>
	<brief_title>A Study Safety , Blood Levels Biological Effects GBT440 Healthy Subjects Subjects With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Healthy male female nonchild bear potential ; 18 55 year old ; nonsmoker use nicotine product within 3 month prior screen . Male female , 18 60 year old , sickle cell disease ( hemoglobin SS , HbS/β0thalassemia , HbS/β+thalassemia , HbSC ) require chronic blood transfusion therapy ; without hospitalization 30 day screen receive blood transfusion within 30 day screen ; subject allow concomitant use hydroxyurea dose stable 3 month prior screen . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder . Subjects consume 14 ( female subject ) 21 ( male subject ) unit alcohol week . Subjects use investigational product clinical trial within 30 day screen Subjects sickle cell disease smoke &gt; 10 cigarette per day ; hemoglobin level &lt; 6 g/dL &gt; 10.4 g/dL ( &gt; ULN ( appropriately correct gender ) Cohort 15 ) screening ; aspartate aminotransferase ( AST ) &gt; 4x upper limit normal alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALK ) &gt; 3x upper limit normal reference range ( ULN ) screening ; moderate severe renal dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>